摘要
目的探讨甲磺酸伊马替尼联合长春地辛+地塞米松+培门冬酶+去甲氧柔红霉素(VDLD)方案治疗小儿急性淋巴细胞白血病的近远期疗效。方法依据治疗药物的不同将77例急性淋巴细胞白血病患儿分为联合组(n=40)和对照组(n=37),联合组患儿给予甲磺酸伊马替尼联合VDLD方案治疗,对照组患儿给予VDLD方案治疗。比较两组患儿的近期疗效、T淋巴细胞亚群水平(CD4^(+)、CD8^(+),计算CD4^(+)/CD8^(+))、不良反应发生情况和预后情况。结果联合组患者的治疗总有效率为92.50%,高于对照组患儿的75.68%,差异有统计学意义(P﹤0.05)。治疗后,两组患儿CD4^(+)、CD8^(+)水平和CD4^(+)/CD8^(+)均高于本组治疗前,且联合组患儿CD4^(+)、CD8^(+)水平和CD4^(+)/CD8^(+)均高于对照组,差异均有统计学意义(P﹤0.05)。联合组患儿不良反应总发生率为15.00%,与对照组患儿的10.81%比较,差异无统计学意义(P﹥0.05)。两组患儿1、3年生存率比较,差异均无统计学意义(P﹥0.05),联合组患儿5年生存率高于对照组,差异有统计学意义(P﹤0.05)。结论甲磺酸伊马替尼联合VDLD方案治疗急性淋巴细胞白血病的临床疗效较好,可改善T淋巴细胞亚群水平和远期预后,且安全性较高。
Objective To investigate the short-term and long-term efficacy of imatinib mesylate combined with vindesine+dexamethasone+pegaspargase+daunorubicin(VDLD)regimen in the treatment of children with acute lymphoblastic leukemia(ALL).Method A total of 77 children with ALL were divided into combined group(n=40)and control group(n=37)according to different treatment drugs.The children in the combined group were treated with imatinib mesylate combined with the VDLD regimen,and the children in the control group were treated with the VDLD regimen.The short-term efficacy,T lymphocyte subset levels(CD4^(+),CD8^(+),calculate CD4^(+)/CD8^(+)),adverse events,and prognosis were compared between the two groups.Result The total effective rate in the combined group was 92.50%,which was higher than 75.68% in the control group,and the difference was statistically significant(P<0.05).After the treatment,the levels of CD4^(+),CD8^(+),and CD4^(+)/CD8^(+) in the two groups were higher than those before the treatment,and the levels of these indicators in the combined group were higher than those in the control group,and the differences were statistically significant(P<0.05).The total incidence of adverse events in the combined group was 15.00%,which was 10.81% in the control group,and the difference was not statistically significant(P>0.05).There was no significant difference in the 1-and 3-year survival between the two groups(P>0.05).The 5-year survival rate in the combined group was higher than that in the control group,and the difference was statistically significant(P<0.05).Conclusion Imatinib mesylate combined with the VDLD regimen has been proven to achieve high clinical efficacy in treating acute lymphoblastic leukemia which could control the level of T lymphocyte subsets,and improve long-term prognosis with reliable safety.
作者
李红
李洋
曹鸿鑫
LI Hong;LI Yang;CAO Hongxin(Department of Pharmacy,Yulin No.2 Hospital,Yulin 719000,Shaanxi,China;Department of Pharmaceutical,Yulin No.2 Hospital,Yulin 719000,Shaanxi,China;Department of Oncology,Yulin No.2 Hospital,Yulin 719000,Shaanxi,China)
出处
《癌症进展》
2022年第16期1704-1707,共4页
Oncology Progress
